Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)

Next Previous
Trial Profile

BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risankizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms IMMhance
  • Sponsors AbbVie; Boehringer Ingelheim; Boehringer Ingelheim Pharma KG

Most Recent Events

  • 21 Mar 2023 Results of pooled analysis (n=1306 from four studies UltIMMa-1 and -2, IMMvent, and IMMhance) assessing racial and ethnic diversity for efficacy and safety outcomes presented at the American Academy of Dermatology annual Meeting 2023
  • 25 Apr 2021 Results of an analysis assessing the efficacy and safety of Risankizumab re-treatment after withdrawal compared with continuous long-term Risankizumab treatment using data from the IMMhance and LIMMitless studies presented at the American Academy of Dermatology Virtual Meeting Experience 2021
  • 25 Apr 2021 Results (n=2101) of post-hoc and pooled analysis of four phase III clinical trials (UltIMMa-1, UltIMMa-2, IMMvent, and IMMhance), presented at the American Academy of Dermatology Virtual Meeting Experience 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top